

Highlights of This Issue 1839

THERAPEUTIC DISCOVERY

1841 **First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer**
Leyre Brizuela, Isabelle Ader, Catherine Mazerolles, Magalie Bocquet, Bernard Malavaud, and Olivier Cuvillier

1852 **Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters**
KyoungHyun Kim, Gayathri Chadalapaka, Satya S. Pathi, Un-Ho Jin, Ju-Seog Lee, Yun-Yong Park, Sung-Gook Cho, Sudhakar Chintharlapalli, and Stephen Safe

1863 **A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating Cells**
Yi Chieh Lim, Tara L. Roberts, Bryan W. Day, Angus Harding, Sergei Kozlov, Amanda W. Kijas, Kathleen S. Ensbeys, David G. Walker, and Martin F. Lavin

1873 **Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets**
Mohammad Aslam Khan, Satindra Gahlot, and Sekhar Majumdar

1884 **Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the β GBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective *In Vivo***
Livio Mallucci, Dong-yun Shi, Derek Davies, Peter Jordan, Alastair Nicol, Lavinia Lotti, Renato Mariani-Costantini, Fabio Verginelli, Valerie Wells, and Daniel Zicha

1894 ***Trans,trans,trans*-[Pt^{IV}(N₃)₂(OH)₂(py)(NH₃)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism**
Aron F. Westendorf, Julie A. Woods, Katharina Korpis, Nicola J. Farrer, Luca Salassa, Kim Robinson, Virginia Appleyard, Karen Murray, Renate Grünert, Alastair M. Thompson, Peter J. Sadler, and Patrick J. Bednarski

1905 **Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF- κ B Pathways**
Xinqi Wu, Jingjing Li, Meijun Zhu, Jonathan A. Fletcher, and F. Stephen Hodi

1915 **Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models**
Xinhua Xie, Laisheng Li, Xiangsheng Xiao, Jiaoli Guo, Yanan Kong, Mingqing Wu, Wanli Liu, Guoquan Gao, Jennifer L. Hsu, Weidong Wei, Mien-Chie Hung, and Xiaoming Xie

1925 **ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms**
Nousheen Zaidi, Ines Royaux, Johannes V. Swinnen, and Karine Smans

PRECLINICAL DEVELOPMENT

1936 **Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts**
Muralidharan Anbalagan, Alaa Ali, Ryan K. Jones, Carolyn G. Marsden, Mei Sheng, Latonya Carrier, Yahao Bu, David Hangauer, and Brian G. Rowan

- 1948 **Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin *In Vitro* and *In Vivo* Using BRCA1 and BRCA2 Isogenic Models**
Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O'Connor
- 1959 **TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells**
Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, David J. Liewehr, Seth M. Steinberg, Sandra Silberman, Diane Palmieri, and Patricia S. Steeg
- 1968 **Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target**
Yongli Guo, Fadzai Chinyenetere, Andrey V. Dolinko, Alexandra Lopez-Aguiar, Yun Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freemantle, Angeline S. Andrew, Vincent Memoli, and Ethan Dmitrovsky
- 1978 **Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib**
Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O'Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon, and Richard S. Finn
- 1988 **YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels**
Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar
- 1999 **The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models**
Masamichi Mizuma, Zeshaan A. Rasheed, Shinichi Yabuuchi, Noriyuki Omura, Nathaniel R. Campbell, Roeland F. de Wilde, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra, and N.V. Rajeshkumar
- 2010 **Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells**
Yoko Matsuda, Masahito Hagio, Tomoko Seya, and Toshiyuki Ishiwata
- 2021 **Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion**
Pierre Saintigny, Shaohua Peng, Li Zhang, Banibrata Sen, Ignacio I. Wistuba, Scott M. Lippman, Luc Girard, John D. Minna, John V. Heymach, and Faye M. Johnson
- 2033 **The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2**
Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, Suneet Shukla, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer
- 2045 **MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma**
Judy Quiju Shi, Kerri Lasky, Vaishali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe Nestor, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D' Amore, and Marc L. Hyer
- 2054 **Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility**
Dana Ziliak, Eric R. Gamazon, Bonnie LaCroix, Hae Kyung Im, Yujia Wen, and Rong Stephanie Huang

MOLECULAR MEDICINE IN PRACTICE


- 2062 **Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials**
Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elez, Maria Alsina, Jaume Capdevila, Jose Perez-Garcia, Gessamí Sánchez-Ollé, Claudia Aura, Ludmila Prudkin, Stefania Landolfi, Javier Hernández-Losa, Ana Vivancos, and Josep Taberero

CORRECTION

- 2072 **Correction: Proanthocyanidins Inhibit *In Vitro* and *In Vivo* Growth of Human Non-Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E₂ and Prostaglandin E₂ Receptors**

ABOUT THE COVER

Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.



Molecular Cancer Therapeutics

11 (9)

Mol Cancer Ther 2012;11:1839-2073.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/11/9>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/11/9>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.